Payment overview · 2025
General Payments
$764.02
36 reported records · 10 companies
Healthcare provider profile · identity verified
Kevin L Park, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRYAN, OH · NPI 1063441491
Verified facts
What the public records show
CMS Open Payments records show Kevin L Park, MD received $764.02 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.46 | 34.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $184.09 | 24.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.51 | 14.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.33 | 7.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.79 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.37 | 5.0% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.09 | 3.4% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.00 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.15 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $764.02 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $215.39 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $186.12 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $184.09 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $170.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.76 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.70 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1066 | 258 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 719 | 207 |
| Losartan Potassium | Losartan Potassium | 709 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 706 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 137 |
| Furosemide | Furosemide | 533 | 113 |
| Omeprazole | Omeprazole | 493 | 128 |
| Lisinopril | Lisinopril | 465 | 116 |
| Trazodone Hcl | Trazodone Hcl | 451 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 447 | 119 |
| Famotidine | Famotidine | 418 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 104 |
| Spironolactone | Spironolactone | 362 | 90 |
| Glimepiride | Glimepiride | 338 | 86 |
| Tramadol Hcl | Tramadol Hcl | 285 | 75 |
| Gabapentin | Gabapentin | 278 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 89 |
| Metformin Hcl | Metformin Hcl | 253 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 251 | 62 |
| Sertraline Hcl | Sertraline Hcl | 233 | 43 |
| Carvedilol | Carvedilol | 217 | 59 |
| Eliquis | Apixaban | 213 | 45 |
| Nystop | Nystatin | 211 | 28 |
| Mirtazapine | Mirtazapine | 193 | 39 |
| Prednisone | Prednisone | 185 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 182 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 47 |
| Lorazepam | Lorazepam | 171 | 44 |
| Allopurinol | Allopurinol | 169 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 30 |
| Atenolol | Atenolol | 161 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 43 |
| Clonazepam | Clonazepam | 159 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 53 |
| Donepezil Hcl | Donepezil Hcl | 154 | 20 |
| Buspirone Hcl | Buspirone Hcl | 152 | 29 |
| Warfarin Sodium | Warfarin Sodium | 145 | 30 |
| Metformin Hcl Er | Metformin Hcl | 132 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 24 |
| Xarelto | Rivaroxaban | 116 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 30 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 108 | 30 |
| Memantine Hcl | Memantine Hcl | 107 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 36 |
| Cefuroxime | Cefuroxime Axetil | 105 | 59 |
| Nystatin | Nystatin | 105 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 23 |
| Azithromycin | Azithromycin | 103 | 72 |
| Montelukast Sodium | Montelukast Sodium | 99 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 34 |
| Ezetimibe | Ezetimibe | 95 | 23 |
| Alprazolam | Alprazolam | 94 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 20 |
| Fluconazole | Fluconazole | 87 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 23 |
| Levofloxacin | Levofloxacin | 83 | 55 |
| Bupropion Xl | Bupropion Hcl | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 13 |
| Meloxicam | Meloxicam | 79 | 20 |
| Amoxicillin | Amoxicillin | 77 | 55 |
| Amiodarone Hcl | Amiodarone Hcl | 74 | 18 |
| Divalproex Sodium | Divalproex Sodium | 74 | 14 |
| Jardiance | Empagliflozin | 74 | 23 |
| Simvastatin | Simvastatin | 74 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 13 |
| Potassium Chloride | Potassium Chloride | 72 | 28 |
| Celecoxib | Celecoxib | 69 | 25 |
| Latanoprost | Latanoprost | 69 | suppressed |
| Baclofen | Baclofen | 68 | 18 |
| Finasteride | Finasteride | 67 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 24 |
| Synthroid | Levothyroxine Sodium | 66 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Ozempic | Semaglutide | 64 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Alendronate Sodium | Alendronate Sodium | 57 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 12 |
| Olanzapine | Olanzapine | 56 | 14 |
| Nitroglycerin | Nitroglycerin | 54 | 39 |
| Ondansetron Odt | Ondansetron | 54 | 23 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Timolol Maleate | Timolol Maleate | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 27 |
| Hydrocortisone | Hydrocortisone | 49 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 14 |
| Ketoconazole | Ketoconazole | 48 | 25 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 21 |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 26 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Clotrimazole | Clotrimazole | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Cilostazol | Cilostazol | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 17 |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nyamyc | Nystatin | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 11 |
| Loperamide | Loperamide Hcl | 19 | 13 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $764.02 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Azstarys, BREZTRI, Cologuard Collection Kit, Dyanavel XR, EVENITY, FARXIGA, Kerendia, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOWST, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error